A5001600045- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Sinusitis and nasal conditions
- Olfactory and Sensory Function Studies
- Cardiovascular Syncope and Autonomic Disorders
- Botulinum Toxin and Related Neurological Disorders
- Dental Anxiety and Anesthesia Techniques
- COVID-19 Impact on Reproduction
- Neuroscience of respiration and sleep
- SARS-CoV-2 and COVID-19 Research
- Ophthalmology and Eye Disorders
- Long-Term Effects of COVID-19
- Allergic Rhinitis and Sensitization
- Nasal Surgery and Airway Studies
Wroclaw Medical University
2020-2021
American Headache Society
2020
New York Proton Center
2020
The Migraine in Poland study is the first large scale nationwide cross-sectional online survey of symptoms, approaches to management, treatment patterns, quality life, and sociodemographic characteristics Polish migraine patients' cohort, conducted from August 2021 June 2022.A was designed based on American Prevalence Prevention (AMPP) Study. Participants were recruited through broad advertisement various channels. included questions allowing for diagnosis without aura (MwoA) third edition...
Cranial autonomic symptoms (CASs) include lacrimation, conjunctival injection, rhinorrhea, nasal congestion, facial flushing or sweating, ptosis, and myosis. These may be associated with trigeminal cephalalgias (TACs) migraine.
The identification of patients who can benefit the most from available preventive treatments is important in chronic migraine. We explored rate excellent responders to onabotulinumtoxinA a multicenter European study and predictors such response, according different definitions. A pooled analysis on migraineurs treated with followed-up for, at least, 9 months was performed. Excellent were defined either as ≥75% decrease monthly headache days (percent-based responders) or <4 (frequency-based...
OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All centers provided patients treated with CM over of treatment. For each cycle we defined as "good responders" if reporting ≥ 50% reduction monthly days compared months before starting...
To quantify wear-off of the response to OnabotulinumtoxinA (OnabotA) treatment over cycle in chronic migraine at group and individual level.OnabotA administered quarterly is an effective for migraine. However, some patients report that headache recurs before scheduled follow-up injection.In this retrospective chart review performed 6 university outpatient centers or private practices specialized treatment, 112 with a ≥30% OnabotA who completed diaries 13 weeks after were included (age [mean...
Abstract Objective To evaluate long‐term reductions in acute headache medication (AHM) use with eptinezumab versus placebo patients prior preventive migraine treatment failures and overuse (MO). Background Preventive is recommended for whom AHMs have failed those who are using excessive amounts of AHM. MO may worsen symptoms people migraine; it a risk factor disease chronification and/or headache. Methods DELIVER was multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled,...
Migraine without aura (MwoA) is often mistaken for rhinosinusitis. The purpose of this study was to assess the prevalence sinonasal symptoms, sinusitis-targeting medication use and burden migraine in a large group people with MwoA attacks accompanied by rhinologic symptoms.Data collected cross-sectional online survey based on an adapted population-based questionnaire. analysis included rhinorrhea, mucopurulent nasal discharge, congestion, facial pressure tenderness palpation,...
Despite its inclusion in the International Classification of Orofacial Pain, tension-type orofacial pain has little support scientific literature. However, a similar-in-phenotype perceived middle segment face been described by few case series from mostly ear, nose and throat clinics. The authors these descriptions used term ‘midfacial pain’. Patients had no significant sinonasal disorder studies, but experienced symmetrical over maxillary ethmoid sinuses. No aura or autonomic symptoms were...
Migraine is mostly a female disorder because of its lower prevalence in men. Less than 20% patients included the available studies on migraine treatments are men; hence, evidence might not apply to The aims present study were provide reliable information effectiveness onabotulinumtoxinA (BT-A) for chronic men and compare clinical benefits between women. We performed pooled patient-level gender-specific analysis real-life data BT-A followed-up 9 months. reported 50% responder rates during...
Background: Midfacial segment pain is a term used in the past diagnosis of patients mainly from ear, nose and throat clinics. This type cannot be attributed to other primary or secondary facial pain, but large extent similar tension-type headache with midfacial location. The purpose this study describe phenotype, burden comorbidities multicentre multidisciplinary setting. ultimate goal comprehensive description allowing for its implementation future classifications. Methods: cross-sectional...
There is currently a wide therapeutic arsenal for migraine patients, without single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national guidelines, previous treatments personal experiences. Our objective was to evaluate differences in use of between neurologists from countries.This multi-centre observational study carried out by specialized headache units seven countries, retrospective with consecutive inclusion all...